Analysts Issue Forecasts for CBIO Q3 Earnings

Crescent Biopharma, Inc. (NASDAQ:CBIO) – Stock analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Crescent Biopharma in a research note issued to investors on Monday, August 11th. HC Wainwright analyst M. Kapoor expects that the biopharmaceutical company will post earnings per share of ($1.29) for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Crescent Biopharma’s Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($8.43) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($5.49) EPS.

CBIO has been the topic of several other reports. Wedbush assumed coverage on Crescent Biopharma in a research report on Monday, July 14th. They issued an “outperform” rating and a $27.00 target price on the stock. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research report on Friday, June 20th. Lifesci Capital raised Crescent Biopharma to a “strong-buy” rating and set a $22.00 target price on the stock in a research report on Wednesday, June 18th. Stifel Nicolaus assumed coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Wall Street Zen lowered Crescent Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $25.50.

Crescent Biopharma Stock Up 0.2%

CBIO stock opened at $13.93 on Wednesday. The firm has a market capitalization of $272.33 million, a PE ratio of -0.40 and a beta of 1.51. The business’s fifty day simple moving average is $13.88. Crescent Biopharma has a 52-week low of $10.83 and a 52-week high of $63.00.

Crescent Biopharma (NASDAQ:CBIO) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($4.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.69) by ($2.24).

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP purchased a new position in Crescent Biopharma in the second quarter valued at about $7,322,000. Affinity Asset Advisors LLC purchased a new position in Crescent Biopharma in the second quarter valued at about $4,520,000. Finally, Jefferies Financial Group Inc. purchased a new position in Crescent Biopharma in the second quarter valued at about $437,000. 75.19% of the stock is owned by hedge funds and other institutional investors.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.